Business
ABIONYX Pharma Launches Fully Secured Capital Increase with Preferential Subscription Rights and Structured Debt Financing for an Aggregate Amount of up to c. EUR 33 M
ABIONYX Pharma Launches Fully Secured Capital Increase with Preferential Subscription Rights and Structured Debt Financing for an Aggregate Amount of up to c.
About this update from Abionyx Pharma Sa
[{"type":"text","content":"\nRegulatory News:\n\n\nABIONYX Pharma (FR0012616852 – ABNX – eligible for PEA-PME) (“Abionyx” or the “Company”), a next-generation biopharmaceutical company developing innovative therapies in sepsis and critical care based on its exclusive apoA-I technology platform, today announced the launch of a capital increase with preferential subscription rights for an amount of EUR 18.7 million secured at 100 % (the “Rights Issue”). The Rights Issue consists of the issuance of new ordinary shares (the “New Shares”) through a capital increase with preferential subscription rights, in accordance with the 17th resolution of the Annual General Shareholders’ Meeting held on June 27, 2024 (the “General Meeting”).\n\n\nIn parallel with the Rights Issue, the Company has entered into a subscription agreement with Fenja Capital (“Fenja”), an independent asset manager based in Denmark focused on investing in innovative companies in healthcare, biotech, and technology, for an unsecured Bonds Financing transaction for a total amount of up to EUR 14 million, consisting of the issuance of two tranches of non-convertible bonds including a first tranche of up to EUR 10 million (the “First Tranche”) and a second tranche of up to EUR 4 million (the “Second Tranche” and, with the First Tranche, the “Bonds”) as well as share warrants (the “Warrants”) giving the right to subscribe for new ordinary shares (respectively, the “Bonds Issuance” and the “Warrants Issuance” and, together, the “Bonds Financing”). Fenja also participates as a guarantor in the Rights Issue.\n\n\nThe proceeds of the Rights Issue and the Bonds Financing (together, the “Transaction”) are expected to result in total cumulative gross proceeds of up to EUR 28.7 million in immediate new funding for the Company (and EUR 32.7 million in case of drawdown of the Second Tranche). The Company could receive additional proceeds if the Warrants are exercised by Fenja.\n\n\nThe Rights Issue is being carried out pursuant to the delegation granted by the General Meeting under its 17th resolution and used by the Board of Directors by a decision dated May 26, 2026, and the Chief Executive Officer by a decision dated May 26, 2026.\n\n\nThe Bonds Issuance is being carried out by a decision of the Board of Directors dated May 26, 2026.\n\n\nThe Warrants Issuance is being carried out pursuant to the delegatio...